サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1513199

非増殖糖尿病性網膜症の世界市場レポート 2024年

Non-Proliferative Diabetic Retinopathy Global Market Report 2024
出版日: | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.72円
非増殖糖尿病性網膜症の世界市場レポート 2024年
出版日: 2024年07月15日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

非増殖糖尿病性網膜症の市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR8.1％で35億8,000万米ドルに成長します。予測期間中に予想される成長は、遠隔医療の普及、治療イノベーションの進展、人工知能の統合、研究開発投資の増加、ヘルスケアインフラの拡大など、いくつかの要因によって促進されます。予測期間に予想される主な動向には、スクリーニングと診断のための人工知能の採用の増加、遠隔医療と遠隔モニタリングソリューションの需要増加、糖尿病網膜症治療に合わせた個別化医療アプローチの出現、予防戦略と早期介入の重視の高まり、糖尿病網膜症の治療における患者中心のケアモデルの役割拡大が含まれます。

糖尿病の罹患率の増加は、今後の非増殖糖尿病性網膜症市場の成長を牽引すると予想されます。糖尿病は、血糖値の上昇を特徴とする慢性の代謝疾患であり、膵臓によるインスリン産生が不十分であるか、体内の細胞がインスリンの作用に対して抵抗性を示すようになることが原因です。座りがちなライフスタイル、食生活の乱れ、遺伝的素因などが糖尿病の主な原因となっています。糖尿病の合併症である非増殖糖尿病性網膜症は、高いグルコースレベルに長期間さらされることによって網膜の血管が損傷し、視力障害や失明の可能性につながります。例えば、2021年11月に国際糖尿病連合が発表したデータによると、2021年時点で20～79歳の成人の約5億3,700万人が糖尿病を患っており、2030年には6億4,300万人、2045年には7億8,300万人に増加すると予測されています。したがって、糖尿病の有病率の増加が非増殖糖尿病性網膜症市場の成長を促進しています。

非増殖糖尿病性網膜症市場の主なプレーヤーは、患者の予後を改善し、眼科イメージングに革命をもたらすAI対応カメラの開発に注力しています。人工知能アルゴリズムを搭載したこれらのカメラは、診断や治療を目的とした眼球画像の撮影、分析、解釈を支援します。例えば、フィンランドの医療技術企業であるオプトメッド社は、2024年5月、軽度段階を超えた糖尿病網膜症を即座に検出するように設計されたハンドヘルドAI眼底カメラ、オプトメッド・オーロラAEYEを発表しました。この革新的なデバイスは、携帯性と人工知能のパワーを組み合わせ、様々な眼疾患の早期発見とモニタリングのための高品質な網膜画像を提供します。オプトメッド・オーロラAEYEは、AIアルゴリズムを活用して医療従事者の網膜画像の解析を支援し、糖尿病網膜症、緑内障、加齢黄斑変性などの疾患の迅速かつ正確な診断を可能にします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の市場規模と成長

  • 世界の非増殖糖尿病性網膜症市場：促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の非増殖糖尿病性網膜症市場の実績：規模と成長, 2018-2023
  • 世界の非増殖糖尿病性網膜症市場の予測：規模と成長, 2023-2028, 2033F

第6章 市場セグメンテーション

  • 世界の非増殖糖尿病性網膜症市場：治療タイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 抗血管内皮増殖因子（VEGF）療法
  • 眼内ステロイド注射
  • レーザー手術
  • 硝子体切除術
  • 世界の非増殖糖尿病性網膜症市場：疾患重症度別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 軽度非増殖糖尿病性網膜症
  • 中程度非増殖糖尿病性網膜症
  • 重度非増殖糖尿病性網膜症
  • 世界の非増殖糖尿病性網膜症市場：エンドユーザー別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 病院
  • 専門クリニック
  • 外来手術センター
  • その他のエンドユーザー

第7章 地域別・国別分析

  • 世界の非増殖糖尿病性網膜症市場：地域別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 世界の非増殖糖尿病性網膜症市場：国別、実績と予測, 2018-2023, 2023-2028F, 2033F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 非増殖糖尿病性網膜症市場：競合情勢
  • 非増殖糖尿病性網膜症市場：企業プロファイル
    • Pfizer Inc.
    • Johnson & Johnson
    • F. Hoffmann-La Roche AG
    • AbbVie Inc.
    • Bayer AG

第31章 その他の大手企業と革新的企業

  • Abbott Laboratories
  • Novartis AG
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Regeneron Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Genentech Inc.
  • Carl Zeiss Meditec AG
  • ZEISS Group
  • Santen Pharmaceutical Co. Ltd.
  • Santen Inc.
  • Topcon Corporation
  • Lumenis Ltd.
  • Alimera Science

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

目次
Product Code: r18186

Non-proliferative diabetic retinopathy (NPDR) stands as a prevalent complication of diabetes mellitus, impacting the retina-the light-sensitive tissue lining the rear of the eye. NPDR manifests through alterations in the retina's blood vessels due to prolonged exposure to elevated blood sugar levels (hyperglycemia) associated with diabetes. Its management involves a blend of medical interventions, lifestyle adjustments, and routine eye examinations aimed at halting disease progression and preserving vision.

The primary treatments for non-proliferative diabetic retinopathy encompass anti-vascular endothelial growth factor (VEGF) therapy, intraocular steroid injection, laser surgery, and vitrectomy. Anti-vascular endothelial growth factor (VEGF) therapy entails the administration of medications that impede vascular endothelial growth factor (VEGF) to deter abnormal blood vessel growth within the retina. This treatment is prescribed across varying severity levels, including mild, moderate, and severe non-proliferative diabetic retinopathy, and is typically administered in hospitals, specialized clinics, ambulatory surgical centers, and similar healthcare settings.

The non-proliferative diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides non-proliferative diabetic retinopathy market statistics, including non-proliferative diabetic retinopathy industry global market size, regional shares, competitors with a non-proliferative diabetic retinopathy market share, detailed non-proliferative diabetic retinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the non-proliferative diabetic retinopathy industry. This non-proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.43 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased prevalence of diabetes, aging population, improved awareness, research advancements, lifestyle changes and improved diabetes management.

The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The anticipated growth in the forecast period is fueled by several factors, including the uptake of telemedicine, advancements in therapeutic innovations, integration of artificial intelligence, heightened investments in research and development, and the expansion of healthcare infrastructure. Key trends expected in the forecast period encompass the rising adoption of artificial intelligence for screening and diagnosis, increased demand for telemedicine and remote monitoring solutions, the emergence of personalized medicine approaches tailored for diabetic retinopathy treatment, a growing emphasis on preventive strategies and early intervention, and an expanding role for patient-centered care models in the management of diabetic retinopathy.

The increasing incidence of diabetes is anticipated to drive the growth of the non-proliferative diabetic retinopathy market in the future. Diabetes, a chronic metabolic disorder characterized by elevated blood glucose levels, results from insufficient insulin production by the pancreas or the body's cells becoming resistant to insulin's effects. Sedentary lifestyles, poor dietary habits, and genetic predispositions are among the leading causes of diabetes. Non-proliferative diabetic retinopathy, a complication of diabetes, occurs when the blood vessels in the retina are damaged due to prolonged exposure to high glucose levels, leading to vision impairment and potential blindness. For example, data from the International Diabetes Federation in November 2021 revealed that approximately 537 million adults aged 20-79 years were living with diabetes in 2021, a number projected to rise to 643 million by 2030 and 783 million by 2045. Hence, the increasing prevalence of diabetes is fueling the growth of the non-proliferative diabetic retinopathy market.

Key players in the non-proliferative diabetic retinopathy market are focusing on developing AI-enabled cameras to enhance patient outcomes and revolutionize ophthalmic imaging. These cameras, equipped with artificial intelligence algorithms, aid in capturing, analyzing, and interpreting eye images for diagnostic and therapeutic purposes. For instance, in May 2024, Optomed, a Finland-based medical technology company, introduced Optomed Aurora AEYE, a handheld AI fundus camera designed to instantly detect diabetic retinopathy beyond mild stages. This innovative device combines portability with the power of artificial intelligence to deliver high-quality retinal images for early detection and monitoring of various eye conditions. The Optomed Aurora AEYE utilizes AI algorithms to assist healthcare professionals in analyzing retinal images, enabling swift and accurate diagnosis of conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration.

In January 2022, Meteda S.r.l., an Italy-based nutrition solutions company, acquired Retmarker SA to strengthen its position in providing innovative solutions for chronic diseases such as diabetes, particularly in diabetic retinopathy screening. This strategic move enhances Meteda's ability to address healthcare needs on a broader scale and prevent blindness among individuals with diabetes worldwide. Retmarker SA, a Portugal-based biotechnology company, specializes in developing medical devices serving as biomarkers for the progression of diabetic retinopathy.

Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.

North America was the largest region in the non-proliferative diabetic retinopathy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-proliferative diabetic retinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-proliferative diabetic retinopathy (NPDR) market consists of revenues earned by entities by providing services such as ophthalmological consultations, optometric services, contract research services, and counselling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-proliferative diabetic retinopathy (NPDR) market also includes sales of fundus cameras, optical coherence tomography (OCT) machines, laser photocoagulation equipment, and injections. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Proliferative Diabetic Retinopathy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-proliferative diabetic retinopathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-proliferative diabetic retinopathy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-proliferative diabetic retinopathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Intraocular Steroid Injection; Laser Surgery; Vitrectomy
  • 2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy; Moderate Non-Proliferative Diabetic Retinopathy; Severe Non-Proliferative Diabetic Retinopathy
  • 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Proliferative Diabetic Retinopathy Market Characteristics

3. Non-Proliferative Diabetic Retinopathy Market Trends And Strategies

4. Non-Proliferative Diabetic Retinopathy Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Non-Proliferative Diabetic Retinopathy Market Size and Growth

  • 5.1. Global Non-Proliferative Diabetic Retinopathy Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Non-Proliferative Diabetic Retinopathy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Non-Proliferative Diabetic Retinopathy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Non-Proliferative Diabetic Retinopathy Market Segmentation

  • 6.1. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Anti-Vascular Endothelial Growth Factor (VEGF) Therapy
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy
  • 6.2. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Mild Non-Proliferative Diabetic Retinopathy
  • Moderate Non-Proliferative Diabetic Retinopathy
  • Severe Non-Proliferative Diabetic Retinopathy
  • 6.3. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Other End-Users

7. Non-Proliferative Diabetic Retinopathy Market Regional And Country Analysis

  • 7.1. Global Non-Proliferative Diabetic Retinopathy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Non-Proliferative Diabetic Retinopathy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market

  • 8.1. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Non-Proliferative Diabetic Retinopathy Market

  • 9.1. China Non-Proliferative Diabetic Retinopathy Market Overview
  • 9.2. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Non-Proliferative Diabetic Retinopathy Market

  • 10.1. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Non-Proliferative Diabetic Retinopathy Market

  • 11.1. Japan Non-Proliferative Diabetic Retinopathy Market Overview
  • 11.2. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Non-Proliferative Diabetic Retinopathy Market

  • 12.1. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Non-Proliferative Diabetic Retinopathy Market

  • 13.1. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Non-Proliferative Diabetic Retinopathy Market

  • 14.1. South Korea Non-Proliferative Diabetic Retinopathy Market Overview
  • 14.2. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Non-Proliferative Diabetic Retinopathy Market

  • 15.1. Western Europe Non-Proliferative Diabetic Retinopathy Market Overview
  • 15.2. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Non-Proliferative Diabetic Retinopathy Market

  • 16.1. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Non-Proliferative Diabetic Retinopathy Market

  • 17.1. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Non-Proliferative Diabetic Retinopathy Market

  • 18.1. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Non-Proliferative Diabetic Retinopathy Market

  • 19.1. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Non-Proliferative Diabetic Retinopathy Market

  • 20.1. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Non-Proliferative Diabetic Retinopathy Market

  • 21.1. Eastern Europe Non-Proliferative Diabetic Retinopathy Market Overview
  • 21.2. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Non-Proliferative Diabetic Retinopathy Market

  • 22.1. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Non-Proliferative Diabetic Retinopathy Market

  • 23.1. North America Non-Proliferative Diabetic Retinopathy Market Overview
  • 23.2. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Non-Proliferative Diabetic Retinopathy Market

  • 24.1. USA Non-Proliferative Diabetic Retinopathy Market Overview
  • 24.2. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Non-Proliferative Diabetic Retinopathy Market

  • 25.1. Canada Non-Proliferative Diabetic Retinopathy Market Overview
  • 25.2. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Non-Proliferative Diabetic Retinopathy Market

  • 26.1. South America Non-Proliferative Diabetic Retinopathy Market Overview
  • 26.2. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Non-Proliferative Diabetic Retinopathy Market

  • 27.1. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Non-Proliferative Diabetic Retinopathy Market

  • 28.1. Middle East Non-Proliferative Diabetic Retinopathy Market Overview
  • 28.2. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Non-Proliferative Diabetic Retinopathy Market

  • 29.1. Africa Non-Proliferative Diabetic Retinopathy Market Overview
  • 29.2. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Non-Proliferative Diabetic Retinopathy Market Competitive Landscape And Company Profiles

  • 30.1. Non-Proliferative Diabetic Retinopathy Market Competitive Landscape
  • 30.2. Non-Proliferative Diabetic Retinopathy Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bayer AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Non-Proliferative Diabetic Retinopathy Market Other Major And Innovative Companies

  • 31.1. Abbott Laboratories
  • 31.2. Novartis AG
  • 31.3. Eli Lilly and Company
  • 31.4. Novo Nordisk A/S
  • 31.5. Regeneron Pharmaceuticals Inc.
  • 31.6. Bausch Health Companies Inc.
  • 31.7. Boehringer Ingelheim International GmbH
  • 31.8. Genentech Inc.
  • 31.9. Carl Zeiss Meditec AG
  • 31.10. ZEISS Group
  • 31.11. Santen Pharmaceutical Co. Ltd.
  • 31.12. Santen Inc.
  • 31.13. Topcon Corporation
  • 31.14. Lumenis Ltd.
  • 31.15. Alimera Science

32. Global Non-Proliferative Diabetic Retinopathy Market Competitive Benchmarking

33. Global Non-Proliferative Diabetic Retinopathy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Non-Proliferative Diabetic Retinopathy Market

35. Non-Proliferative Diabetic Retinopathy Market Future Outlook and Potential Analysis

  • 35.1 Non-Proliferative Diabetic Retinopathy Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Non-Proliferative Diabetic Retinopathy Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Non-Proliferative Diabetic Retinopathy Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer